May 1 (UPI) --Pharmaceutical giant Johnson & Johnson on Wednesday said it is taking steps to resolve a multibillion dollar, cancer-related lawsuit with thousands of individuals over claims that ...
Benzinga - by Vandana Singh, Benzinga Editor. Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ...
A subsidiary of Johnson & Johnson is now proposing to pay approximately $6.48 billion over 25 years as part of a settlement in the U.S. to cover allegations that its baby powder containing talc caused ...
Johnson & Johnson is proposing a $6.5 billion settlement to resolve thousands of lawsuits claiming its talc products caused ovarian cancer. J&J aims to settle the legal claims through a third ...
Johnson & Johnson’s MedTech division said Tuesday it plans to submit an application to the U.S. Food and Drug Administration next year to start clinical trials of its general surgery robot. Ottava, ...
Le géant pharmaceutique américain Johnson & Johnson (J&J) a confirmé mardi ses prévisions pour l'exercice… Le laboratoire américain a annoncé son intention d’acquérir la start-up ...
On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with non–muscle-invasive bladder cancer (NMIBC) ...
Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics to acquire from Numab's shareholders its wholly-owned subsidiary for the global rights ...
03/06 Rapport Therapeutics, soutenu par J&J, vise une valorisation d'environ 637 millions de dollars pour son introduction en bourse aux États-Unis RE 03/06 Rapport Therapeutics, soutenue par J&J ...